Evidence map›Paper›PMID 24216219›Full record

Trial reportClinical trials (London, England)2014

A randomized trial of the clinical utility of genetic testing for obesity: design and implementation considerations.

Catharine Wang, Erynn S Gordon, Catharine B Stack, Ching-Ti Liu, Tricia Norkunas, Lisa Wawak, Michael F Christman, Robert C Green, Deborah J Bowen

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical trials (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Catharine WangaDepartment of Community Health Sciences, Boston University School of Public Health, Boston, MA, USA.
Erynn S Gordon
Catharine B Stack
Ching-Ti Liu
Tricia Norkunas
Lisa Wawak
Michael F Christman
Robert C Green
Deborah J Bowen
Boston University · USCoriell Institute For Medical Research · USHarvard University · US

Funding

Integration of Whole Genome Sequencing into Clinical MedicineU01HG006500 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI GREEN, ROBERT C. · 2012 to 2016
$11.5M
Molecular and Genomic Imaging CenterP50HG003170 · NHGRI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI CHURCH, GEORGE M · 2004 to 2009
$11.5M
Risk Evaluation and Education for Alzheimer's Disease (REVEAL IV)R01HG002213 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI GREEN, ROBERT C. · 1999 to 2012
$7.6M
PARTNERS IN HEALTH AND HOUSING PREVENTION RESEARCH CENTERU48DP001922 · DP · BOSTON UNIVERSITY MEDICAL CAMPUS · PI COX, HAROLD DOUGLAS · 2009 to 2013
$3.4M
Impact of Direct to Consumer Genetic TestingR01HG005092 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI GREEN, ROBERT C., ROBERTS, SCOTT · 2010 to 2012
$1.1M
Characterizing Communicating Genetic Risk Alzheimer'sK24AG027841 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI GREEN, ROBERT C. · 2006 to 2010
$914k
Communication of Genetic and Environmental Risks in Colorectal Cancer PreventionK07CA131103 · NCI · FOX CHASE CANCER CENTER · PI WANG, CATHARINE · 2008 to 2012
$674k
Communicating Genetic Information for ObesityR21HG006073 · NHGRI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WANG, CATHARINE · 2011 to 2012
$471k
NCCDPHP CDC HHS U48 DP001922NCCDPHP CDC HHS U48DP001922NCI NIH HHS K07 CA131103NCI NIH HHS K07CA131103NHGRI NIH HHS HG003170NHGRI NIH HHS HG005092NHGRI NIH HHS HG006500NHGRI NIH HHS HG02213NHGRI NIH HHS P50 HG003170NHGRI NIH HHS R01 HG002213NHGRI NIH HHS R01 HG005092NHGRI NIH HHS R21 HG006073NHGRI NIH HHS U01 HG006500NIA NIH HHS AG27841NIA NIH HHS K24 AG027841
6 · The paper itself

Abstract

backgroundObesity rates in the United States have escalated in recent decades and present a major challenge in public health prevention efforts. Currently, testing to identify genetic risk for obesity is readily available through several direct-to-consumer companies. Despite the availability of this type of testing, there is a paucity of evidence as to whether providing people with personal genetic information on obesity risk will facilitate or impede desired behavioral responses. PURPOSE: We describe the key issues in the design and implementation of a randomized controlled trial examining the clinical utility of providing genetic risk information for obesity.

methodsParticipants are being recruited from the Coriell Personalized Medicine Collaborative, an ongoing, longitudinal research cohort study designed to determine the utility of personal genome information in health management and clinical decision making. The primary focus of the ancillary Obesity Risk Communication Study is to determine whether genetic risk information added value to traditional communication efforts for obesity, which are based on lifestyle risk factors. The trial employs a 2 × 2 factorial design in order to examine the effects of providing genetic risk information for obesity, alone or in combination with lifestyle risk information, on participants' psychological responses, behavioral intentions, health behaviors, and weight.

resultsThe factorial design generated four experimental arms based on communication of estimated risk to participants: (1) no risk feedback (control), (2) genetic risk only, (3) lifestyle risk only, and (4) both genetic and lifestyle risk (combined). Key issues in study design pertained to the selection of algorithms to estimate lifestyle risk and determination of information to be provided to participants assigned to each experimental arm to achieve a balance between clinical standards and methodological rigor. Following the launch of the trial in September 2011, implementation challenges pertaining to low enrollment and differential attrition became apparent and required immediate attention and modifications to the study protocol. Although monitoring of these efforts is ongoing, initial observations show a doubling of enrollment and reduced attrition. LIMITATIONS: The trial is evaluating the short-term impact of providing obesity risk information as participants are followed for only 3 months. This study is built upon the structure of an existing personalized medicine study wherein participants have been provided with genetic information for other diseases. This nesting in a larger study may attenuate the effects of obesity risk information and has implications for the generalizability of study findings.

conclusionsThis randomized trial examines value of obesity genetic information, both when provided independently and when combined with lifestyle risk assessment, to motivate individuals to engage in healthy lifestyle behaviors. Study findings will guide future intervention efforts to effectively communicate genetic risk information.

Indexed as

Genetic Predisposition to DiseaseGenetic TestingPatient SelectionResearch DesignAdolescentAdultAgedAged, 80 and overAlgorithmsClinical ProtocolsFollow-Up StudiesHealth BehaviorHealth Knowledge, Attitudes, PracticeHumansLife StyleLost to Follow-Up

Identifiers

PMID24216219
PMCPMC3946398
OpenAlexW2101138397

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.